Veloxis Pharmaceuticals Presents LCP-Tacro(TM) Phase 3 Data at the American ... - MarketWatch (press release) |
![]() |
MarketWatch (press release) ... central pathology (biopsy) results from the LCP-Tacro(TM) study 3001 a long-term safety and efficacy switch study of LCP-Tacro(TM) in kidney transplant recipients, at the American Society of Nephrology (ASN) Kidney Week Annual Scientific Meeting. |